You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 100 No. 4, OCTOBER 1957 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Nitrofurantoin in Chronic Urinary Tract Infection

ERNEST JAWETZ, M.D., Ph.D.; JAMES HOPPER, Jr., M.D.; DONALD R. SMITH, M.D.

AMA Arch Intern Med. 1957;100(4):549-557.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Nitrofurantoin (Furadantin) has recently become established as a useful drug in urinary tract infections. After oral administration it is excreted in the urine in sufficiently high concentrations to give strong antibacterial effects against many microorganisms which are commonly encountered in urinary tract infections. In spite of the demonstration of nitrofurantoin in the blood by chemical methods,1 no significant antibacterial action in blood has been detected.2 The lack of antimicrobial effect in the blood of persons receiving nitrofurantoin combined with the marked antimicrobial action in their urine defines this drug as a urinary antiseptic, i. e., a substance likely to suppress bacteria in urine but not in tissue. Many studies have dealt with the usefulness of nitrofurantoin in acute and uncomplicated infections of the urinary tract.2-5 Daily doses of from 400 to 800 mg. continued for 3 to 12 days frequently result in the relief of symptoms and . . . [Full Text PDF of this Article]


Author Affiliations

San Francisco

From the Departments of Microbiology, Medicine, and Surgery (Urology), University of California School of Medicine. Professor of Microbiology, Lecturer in Medicine and Pediatrics (Dr. Jawetz); Associate Professor of Medicine (Dr. Hopper), and Clinical Professor of Urology (Dr. Smith).


Footnotes

Submitted for publication May 14, 1957.

Supported by a grant from Eaton Laboratories, Norwich, N. Y.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1957 American Medical Association. All Rights Reserved.